Literature DB >> 9696882

RAS pathways to cell cycle control and cell transformation.

M Malumbres1, A Pellicer.   

Abstract

Ras genes are among the most frequently activated oncogenes in cancer. The corresponding protooncogenes are proteins expressed in the majority of tissues in mammals and have a signal transduction activity. Ras proteins interact with a wide spectrum of regulators and downstream effectors producing different cellular responses, including proliferation, differentiation or apoptosis. This review deals with the most recent advances on the role of Ras in the signal transduction pathway from external signals to the cell cycle and gene expression control. We specially address the new developments on the effect of Ras activation in the regulation of different molecules driving the cell cycle progression. Both positive and negative regulators of the cyclin-dependent kinases (CDK), cyclins and CDK inhibitors, are targets of Ras, giving rise to different effects in the cell cycle progression. These Ras-mediated interactions are an extraordinary example of the complexity of the signal transduction networks and the diversity of pathways used by Ras to propagate molecular signals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696882     DOI: 10.2741/a331

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  58 in total

1.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors.

Authors:  Imanol Arozarena; David Matallanas; María T Berciano; Victoria Sanz-Moreno; Fernando Calvo; María T Muñoz; Gustavo Egea; Miguel Lafarga; Piero Crespo
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

3.  Compartmentalized signaling of Ras in fission yeast.

Authors:  Brian Onken; Heidi Wiener; Mark R Philips; Eric C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

5.  Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis.

Authors:  Piyali Dasgupta; Jiazhi Sun; Sheng Wang; Gina Fusaro; Vicki Betts; Jaya Padmanabhan; Saïd M Sebti; Srikumar P Chellappan
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation.

Authors:  David Matallanas; Victoria Sanz-Moreno; Imanol Arozarena; Fernando Calvo; Lorena Agudo-Ibáñez; Eugenio Santos; María T Berciano; Piero Crespo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 7.  Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

Authors:  James DeGregori
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

8.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

9.  Oncolytic reovirus effectively targets breast cancer stem cells.

Authors:  Paola Marcato; Cheryl A Dean; Carman A Giacomantonio; Patrick W K Lee
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

10.  Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.

Authors:  José M Escandell; Pawan Kaler; M Carmen Recio; Takehiko Sasazuki; Senji Shirasawa; Leonard Augenlicht; José-Luis Ríos; Lidija Klampfer
Journal:  Biochem Pharmacol       Date:  2008-05-08       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.